Immatics
Edit

Immatics

http://www.immatics.com/
Last activity: 25.04.2025
Active
Categories: ActiveBioTechDevelopmentDrugGamingIndustryLegalTechMedtechTechnologyVideo
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.


QUICK FACTS

>250 Team members in Tuebingen and Munich, Germany and Houston, Texas
>200 Targets covering major solid tumors
- 2 proprietary technology platforms, XPRESIDENT® and XCEPTOR®
- 7 proprietary drug discovery programs; 3 of which are in clinical development
- Multiple partnered programs


Read more about Immatics on our homepage: https://immatics.com/


Find us also on Twitter:
Twitter: http://bit.ly/2DFbPre


Legal notice: https://immatics.com/imprint/
Followers
1.34K
Followers
8.99K
Website visits
9.1K /mo.
Mentions
66
Location: Germany, Bavaria, Munich
Employees: 201-500
Total raised: $446.39M
Founded date: 2000
Twitter
Facebook
LinkedIn
Email

Investors 5

Funding Rounds 6

DateSeriesAmountInvestors
11.10.2024-$150M-
28.08.2019-$75M-
04.10.2017Series E$58M-
16.07.2014Series D$45.99M-
15.10.2013Series D$46.45M-
21.09.2010Series C$70.95M-

Mentions in press and media 66

DateTitleDescription
26.04.2025Granite Bio: A New Force in Immunology with $100 Million BackingGranite Bio has burst onto the scene, armed with $100 million in funding. This clinical-stage immunology company is not just another player; it’s a potential game-changer. With a focus on autoimmune diseases, Granite Bio is targeting the ro...
25.04.2025Granite Bio: Immunology Company Debuts With $100 Million In FundingGranite Bio, a clinical-stage immunology company, announced it has emerged from stealth with $100 million in funding. This includes a $30 million Series A led by founding investors Versant Ventures and Novartis Venture Fund and a $70 millio...
27.03.2025Immatics Announces Full Year 2024 Financial Results and Business UpdateRandomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients; first patient randomized and enrollment continues as planned ACTengine® IMA203 TCR-T (PRAME): Phase 1b IMA203 data publ...
18.11.2024Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAMEThe Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics Today, Company discloses first clinical data from the TCR Bispecific molecule, TCER® IM...
18.11.2024Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAMEThe Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics Today, Company discloses first clinical data from the TCR Bispecific molecule, TCER® IM...
08.11.2024Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAMETwo oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics’ TCR-T PRAME franchise to target solid cancers ACTengine® IMA203 demonstrates 54% cORR,...
08.11.2024Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAMETwo oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics’ TCR-T PRAME franchise to target solid cancers ACTengine® IMA203 demonstrates 54% cORR,...
11.10.2024Immatics Secures $150 Million in Public Offering: A Bold Step in Cancer ImmunotherapyIn a significant move for the biopharmaceutical sector, Immatics N.V. has announced the pricing of a public offering that aims to raise $150 million. This offering, which involves 16,250,000 ordinary shares priced at $9.25 each, is a strate...
11.10.2024Immatics Announces Pricing of $150 Million Public OfferingHouston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced t...
10.10.2024Immatics Announces Pricing of $150 Million Public OfferingHouston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced t...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In